I'm not an expert in this area but I think all novel antibiotic trials are non-inferiority. The idea is that we don't need antibiotics that are more effective, we just need new ones so that as bacteria develop resistance to existing drugs, we have something to fall back on.
While the numbers are similar, remember that Trius' drug is a shorter course and only given 1/day. In my mind, if you can give less drug for a shorter period of time and get the same result, that is superior.
Exactly. If it is 'non-inferior'...then it is superior by default. That is the point everyone is missing. It targets bacteria that are resistant to existing treatments. Thus, if it can perform comparitively with existing treatments against non-resistant staph, it IS superior. Not to mention the shorter treatment regiment; smaller dosage; less side effects; etc. If we upped the dose and treatment length comparable to the Pfizer drug...and it proved tolerable, the numbers would be a blowout! It was comparable, even post-treatment, with 4 less treatment days!